Brise Pharmaceutical (Shanghai) Co. Ltd. has discovered carbocyclic or heterocyclic derivatives acting as transient receptor potential cation channel subfamily M member 3 (TRPM3) antagonists.
Pain treatment, especially non-addictive treatment for severe pain, remains a critical unmet need. Among the TRP channels, transient receptor potential cation channel subfamily M member 3 (TRMP3) is a channel expressed in somatosensory neurons, including nociceptors of rodents and humans.